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ScienceDirectProtein lipidation is unique amongst post-translational
modifications (PTMs) in enabling direct interaction with cell
membranes, and is found in every form of life. Lipidation is
important in normal function and in disease, but its intricate
interplay with disease context presents a challenging for drug
development. Global whole-proteome profiling of protein
lipidation lies beyond the range of standard methods, but is
well-suited to metabolic tagging with small ‘clickable’ chemical
reporters that do not disrupt metabolism and function;
chemoselective reactions are then used to add multifunctional
labels exclusively to tagged-lipidated proteins. This chemical
proteomic technology has opened up the first quantitative
whole-proteome studies of the known major classes of protein
lipidation, and the first insights into their full scope in vivo.
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Introduction
Amongst the hundreds of classes of known protein post-
translational modification (PTM) protein lipidation is
unique in enabling direct interaction with cell mem-
branes, ranging from constitutive, stable anchors that
can withstand multiple rounds of endosomal recycling,
to transient membrane binders that permit rapid switch-
ing of subcellular localization. Protein lipidation is found
in every form of life, and has evolved to its most soph-
isticated forms in eukaryotes, in which vesicular traffick-
ing pathways and membrane-bound signaling platforms
are strongly regulated by lipidated protein families.
These PTMs are also important in disease; many of
the enzymes involved in installing and processing proteinCurrent Opinion in Chemical Biology 2015, 24:48–57 lipidation have been targeted for drug discovery, resulting
in a number of clinical trials. However, the complex and
incompletely understood substrate specificity of these
enzymes, and its intricate interplay with lipid metabolism
and disease context, have contributed to a challenging and
thus far inconclusive development process. Numerous
protein lipidation substrates have been discovered to date,
generally through metabolic radiolabeling with lipid pre-
cursors, but the full substrate scope has yet to be deter-
mined for any of the known types of lipidation. In particular,
very few substrates have been validated at endogenous
levels in cells, that is, without resorting to substrate over-
expression which may in itself influence lipidation levels,
and very little is currently known about how changes
induced by genetic mutation, disease or drug treatment
quantitatively affect protein lipidation across the proteome.
Global profiling of protein lipidation lies beyond the
range of most standard bioanalytical methods because
these relatively large and very hydrophobic PTMs pre-
sent challenges in protein isolation and separation, restrict
ionization of peptides and proteins during mass spectro-
metric analysis, and are insensitively labeled by radio-
active isotopes. Fortunately, protein lipidation is
particularly well-suited to analysis through metabolic
chemical tagging, since the large size and hydrophobicity
of these PTMs facilitates modification with small ‘click-
able’ tags whilst avoiding disruption to metabolism and
function (Figure 1) [1–3]. These tags can then be
addressed either in situ or following protein isolation
through one of a set of extremely chemoselective reactions
that add multifunctional labels exclusively to the modified
proteins. Introduction of fluorescent dyes and/or epitope
tags allows extremely rapid and sensitive multi-label
detection, whereas addition of affinity handles (e.g. biotin)
uniquely enables global quantitative analysis of protein
lipidation by enrichment coupled to standard liquid
chromatography-mass spectrometry. In this review we
discuss the development of chemical proteomics technol-
ogies that have resulted in the first quantitative whole-
proteome studies of the known major classes of protein
lipidation, and the first insights into their full scope in vivo.
Protein N-acylation at the N-terminus and at
lysine
The most-well characterized form of protein N-acylation is
N-terminal N-myristoylation, the irreversible attachmentwww.sciencedirect.com
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A common workflow can be used to address each of the common classes of lipidation, enabling a wide range of readouts including imaging, pull-
downs and mass spectrometry. Rapid profiling and comparisons across experimental conditions or imaging of specific substrates through
adaption of the DuoLink proximity rolling-circle amplification technology. The use of selective tool inhibitors and genetic manipulation (e.g. enzyme
knockdown or knockout) is used to validate substrates and to quantify the degree of cross-talk between pathways. In combination with stable
isotope labeling (SILAC) this approach can be used to quantify changes in lipidation state for proteins across the proteome in response to disease
state or drug action, and is applicable to any metabolically active system, including cell lines and in vivo models.of a C14-fatty acid (myristate) to the N-terminal glycine of
substrate proteins, which is catalyzed by N-myristoyltrans-
ferase (NMT) [4]. NMT is encoded by a single copy gene
in lower eukaryotes, whereas in humans and most other
higher organisms two NMT genes (nmt1 and nmt2) have
been identified. Protein N-myristoylation increases affinity
for membranes and is required for viability and survival in
every organism in which its essentiality has been studied.
Dysregulation of myristoylated proteins has been linked to
several diseases and NMT has been proposed as a poten-
tial drug target in viral, fungal, bacterial or parasitic infec-
tions, as well as in cancer [4]. Chemical tools have beenwww.sciencedirect.com developed to study N-myristoylation, including alkyne and
azido-tagged analogues of the natural lipid substrate
(YnMyr and AzMyr, respectively) [5], as well as competi-
tive inhibitors of the protein binding site of NMT. YnMyr
is used in most recent studies as it is known to give minimal
background labeling [6], and alkyne-tagged lipids appear
to recapitulate endogenous lipid metabolism [7]. Potent
NMT inhibitors have also been reported, for example
against NMT from yeast [8] and from Trypanosoma brucei
(the causative agent of human sleeping sickness) [9,10],
although these had variable selectivity against NMT from
various species. More selective inhibitors have beenCurrent Opinion in Chemical Biology 2015, 24:48–57
50 Omicsreported recently [11], and can be used as selective chemi-
cal tools to pharmacologically knockdown N-myristoyla-
tion in different organisms. However, metabolism (e.g.
chain elongation) of N-myristoylation probes can result
in trafficking into unrelated lipidation pathways including
GPI anchors and S-palmitoylation (see following sections).
In this context, the combination of NMT inhibitors with
YnMyr and quantitative proteomic analysis has proven
particularly powerful in establishing the N-myristoylated
proteome in vivo, without interference by off-target protein
labeling. In this approach, the response of YnMyr-tagged
proteins to selective NMT inhibitors is quantified, and
correlated with the identification of each protein as a
substrate or non-substrate of NMT.
In the first study of this type, this technology was applied
to live malaria parasites and identified about 30 NMT
substrates across the proteome, the large majority for the
first time, highlighting the potential for de novo substrate
identification [12]. YnMyr labeling was also used to
demonstrate that NMT inhibitors acted on-target in live
parasites, and to validate NMT as an antimalarial drug
target. A further refinement used chemical proteomic
tools that enabled direct identification of the site of N-
myristoylation, resulting in direct identification of the co-
translationally and post-translationally N-myristoylated
proteomes of human cells using a NMT inhibitor com-
bined with quantitative chemical proteomics [13]. More
than 100 NMT substrates were directly identified in this
study, >90% for the first time at endogenous protein
levels, along with quantitative in-cell IC50 inhibition pro-
files for most of these proteins. Notably, monitoring myr-
istoylation during induction of apoptosis identified
40 substrates that are N-myristoylated post-translationally
at an internal site, mainly following caspase cleavage, and
these proteins may have a specific role in mediating this
important cellular process. In the future, a similar approach
could be applied to establish the substrate specificity of the
NMT1 and NMT2 isozymes in human cells.
The context of human infection recently provided the
first example of reversal of N-terminal N-myristoylation;
in this study, enzymatic treatment of YnMyr-tagged cell
lysates revealed that the N-myristoylglycine moiety can
be hydrolyzed by a secreted bacterial effector protein
with cysteine protease activity, the Shigella virulence
factor IpaJ [14]. This process is itself irreversible since
the N-terminal glycine is also cleaved from the protein,
and allows Shigella to exploit host trafficking pathways
during bacterial infection. In the future, IpaJ may also
prove a useful and complementary tool for analysis of
N-acylation, although its substrate scope has yet to be
determined in cells (Figure 2).
N-Acylation is also known to occur at the N-terminal
cysteine of the hedgehog (Hh) protein family; Hh signaling
is mostly inactive in healthy adults but is reactivated inCurrent Opinion in Chemical Biology 2015, 24:48–57 various cancers, and the Hh pathway is a widely studied
anticancer drug target with many inhibitors in clinical trials
(see also protein cholesterylation, below) [15]. Acylation is
catalyzed by a Hh-specific enzyme, hedgehog-acyltrans-
ferase (HHAT), a multi-pass transmembrane protein in the
membrane bound O-acyltransferase (MBOAT) family.
Whilst the large majority of MBOATs transfer lipids to
hydroxyls during lipid processing (and in a few cases to
proteins, see O-acylation), HHAT S-palmitoylates Hh
proteins at an N-terminal cysteine; this initial thioester
rapidly rearranges through S-to-N acyl shift to produce the
mature N-terminal N- palmitoyl Hh [16]. Hh N-palmitoy-
lation is an excellent target for chemical tagging with azide
or alkyne-tagged analogues, and several studies have used
this approach to date to demonstrate the essentiality of
HHAT and its role in Hh signaling [16,17]. A putative
cell-active tool inhibitor for HHAT was also recently
reported [18], although its selectivity and stability remain
to be proven in vivo.
Long-chain fatty acids including myristic acid have also
been reported at lysine side-chains in a process that is
thought to be independent of NMT, for example on
interleukin 1 alpha and tumor necrosis factor (TNF)
alpha [19,20]. A combination of biochemical experiments
and alkyne-tagged fatty acid labeling experiments was
used to explore the function of this post-translational
modification, and NAD-dependent protein deacetylase
sirtuin-6 (SIRT6) was shown to hydrolyze myristoyl and
possibly other long chain acyl moieties on specific resi-
dues of TNF-alpha, which regulates the secretion of
TNF-alpha [21]. Subsequently, a wide range of sirtuins
was shown to have long chain N-acyllysine deacylating
activity in an isolated enzyme system [22,23]. The
enzyme(s) that may act as transferases in this process
have yet to be identified, and there remains the possibility
that the phenomenon is the result of non-specific attack
by reactive acyl-CoA precursors [24]; in this view, the
sirtuins may mediate a damage limitation mechanism,
with a co-evolved regulatory effect on protein function for
certain substrates. Furthermore, given the very broad
substrate range of the sirtuins in vitro, there is an emer-
ging consensus that their roles can only be determined in
vivo, which will require more selective Sirt inhibitors and
advances in chemical proteomic technology to identify
sites of N-acylation. Further studies are also needed to
identify any enzymes that may be involved in incorpora-
tion of long-chain fatty acids on lysine side-chains.
Protein S-acylation at cysteine
S-Acylation occurs through a thioester linkage at
cysteines, and is regulated through acylation by protein
acyltransferases (PATs) and removal by a small number of
broad-spectrum acyl-protein thioesterases (APTs)
[25,26,27]. The major chain is thought to be C16:0
and thus this modification is often termed S-palmitoyla-
tion, but other chain types are also known and specificwww.sciencedirect.com
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Structures and known scope of the major forms of protein lipidation. Each type of lipidation is involved in important disease pathways in addition
to basal cellular function and development, and all types can be profiled in cells using the common technology platform outlined in Figure 1, for
the discovery and elucidation of substrate scope and function.determination of chain length or saturation state is very
rarely performed due to challenges of analysis. In
addition, non-enzymatic chemical S-acylation is very
likely to occur to a significant extent based on the avail-
ability of acyl-CoA in the cell, although this route remains
poorly characterized, and by analogy to the sirtuins (see
N-acylation) it is plausible that a major role for the APTs
is the constitutive repair of this metabolic damage [24].www.sciencedirect.com Long-chain S-acylation is widespread in eukaryotes, and
there are upwards of 500 S-acylated proteins known in
humans; furthermore, the modification state of a given
protein is typically not uniform, allowing regulation of
localization and activity. Enzymatic S-palmitoylation is
predominantly performed by DHHC-motif containing
PATs (DHHCs), which are implicated in disease states
including Alzheimer’s disease and cancer [28]. To date,Current Opinion in Chemical Biology 2015, 24:48–57
52 Omicsthere is no potent or selective inhibitor available for the
DHHC class. 2-bromopalmitate (2BP) is often erro-
neously deployed as a pan-DHHC tool inhibitor, despite
longstanding evidence that its effects are mediated large-
ly through disruption of lipid metabolism [29]. Recent
chemical probe studies have demonstrated that 2BP
covalently modifies upwards of 450 proteins only a few
of which are DHHCs [30,31], strongly implying that
2BP should not be employed in the study of S-palmitoy-
lation. In contrast, a series of recently described selective
APT inhibitors [32,33] serve as very useful tools for
S-palmitoylation studies, extending to applications in
vivo [34].
S-Acylation is most often studied through ‘cysteine-cen-
tric’ approaches, where acyl groups are exchanged for
reporters, or ‘acyl-centric’ approaches, using metabolic
incorporation of chemically tagged acyl chains [26].
‘Cysteine-centric’ approaches, including acyl-biotin
exchange (ABE [35]) and acyl-resin assisted capture
(acyl-RAC [36]), will detect any base-labile thiol modi-
fication (including S-acylation) in cell lysates, and cannot
distinguish between these modifications. Here, free
cysteines are capped with thiol reactive reagents and
modified cysteines revealed though hydroxylamine
hydrolysis, for reaction with thiol-reactive biotin
analogues or resins. Recent reports in the application
of cysteine-centric approaches include identification of
palmitoylated superoxide dismutase (SOD1, important in
protecting cells from oxidative damage) in endothelial
cells [37], and profiling of potentially palmitoylated
proteins in adipocytes and adipose tissue [38]. Since this
methodology improves detection by liquid chromatog-
raphy–coupled mass spectrometry by removing the lipid
from specifically modified peptide, the site of palmitoyla-
tion can sometimes be determined. Although initial
efforts in this direction have resulted in modest coverage
of up to 170 sites among 400 proteins [36,39], it should be
expected that further optimization of proteomic work-
flows will soon enable whole-proteome analysis of site
occupancy by S-acylation.
Weaknesses of the cysteine-centric approach include
inability to positively identify the modification (since it
is lost during analysis), a high false positive rate from
background cysteine reactivity, and limited time resol-
ution for dynamic palmitoylation. Direct metabolic
incorporation of chemically tagged palmitate is an alterna-
tive acyl-centric approach that enables facile pulse-chase
quantification of dynamic and static S-acylation [26],
but is subject to fluctuations in lipid processing, and
incubation with a relatively high concentration of tagged
lipid may influence metabolic state. However, a recent
report demonstrated that a combination of acyl-centric
and cysteine-centric approaches can provide enhanced
confidence in assigning targets of S-acylation [40]. In
the major human malaria parasite, Plasmodium falciparum,Current Opinion in Chemical Biology 2015, 24:48–57 the authors revealed both dynamic and stable S-acylation
across more than 400 proteins, including key factors in
disease. This combined approach is well-suited to any
system amenable to culture in vitro, and should be
adopted by default if maximum confidence is a primary
concern.
Protein S-Prenylation at cysteine
Protein S-prenylation, the attachment of a farnesyl (C15)
or geranylgeranyl (C20) isoprenoid, occurs via a thioether
bond on cysteine residues, typically near the C-terminus
of target proteins. Farnesyl transferase (FTase) and ger-
anylgeranyl transferase type 1 (GGTase-1) prenylate
C-terminal CAAX motifs, whereas Rab geranylgeranyl
transferase (RabGGTase/GGTase-2) attaches one or two
geranylgeranyl groups to a variety of cysteine-containing
sequences specifically in Rab proteins, and requires the
accessory proteins Rab Escort Protein 1 or 2 (Rep1/2).
Protein prenylation is widely conserved in eukaryotes,
and substrates include the large Ras, Rho and Rab
families of GTPases, nuclear lamins as well as a number
of kinases and phosphatases. In addition, certain viral [41]
and bacterial effector [42] proteins are known to be
prenylated by the host cell upon infection. Prenylation
has been widely studied as a drug target in cancer [43] and
progeria [44], with prenyl transferase inhibitors (PTIs)
entering more than 70 clinical trials [45]; as a result, a
plethora of inhibitor classes is available for these
enzymes, with the notable exception of RabGGTase
for which a highly selective and potent inhibitor has
yet to be fully validated in cells [46]. To date the
performance of PTIs in the clinic has been limited at
least in part due to specific inhibition driving abnormal
and compensatory prenylation by the other prenyltrans-
ferases. The wide range of PTIs used as tools in cell
biology studies raises a challenge in interpretation and
reproducibility, since the potency and selectivity of most
of these inhibitors has not been established in a relevant
cellular context. As isoprenoids are intermediates of the
mevalonate pathway, prenylation is also inhibited by
statins (HMG-CoA reductase inhibitors) and this is
thought to contribute to the therapeutic effects of this
class of drugs [47].
Over the years a large number of chemical reporters to
study prenylation have been reported, with recent
examples incorporating fluorophores [48], affinity handles
[49] or chemical tags for bioorthogonal ligation [50,51].
Such analogues lend themselves to two distinct appli-
cations: in vitro prenylation of purified proteins or in cell
lysates, typically using exogenous recombinant prenyl-
transferase, or in-cell experiments through metabolic
labeling.
In vitro prenylation has been used by our lab and others to
study the misprenylation of Rabs in models of Choroi-
deremia, a disease resulting from the genetic deletion ofwww.sciencedirect.com
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the eye, leading to retinal degeneration and ultimately
blindness. The rate of prenylation of various Rab proteins
in lysates was also used to establish cell-free prenylation
efficiency for different members of the Rab family [52].
Although in-lysate prenylation is suited to systems cur-
rently inaccessible to metabolic labeling (e.g. patient
samples and animal models) it is technically complex
to implement and relies on identifying proteins that were
not prenylated. As such any information on what sub-
strates are prenylated in vivo can only be inferred; in
particular, cross-talk between different types of prenyla-
tion during PTI treatment cannot be recapitulated. Sec-
ondly, the method is restricted to studying non-
equilibrium systems, since it requires an abundance of
non-prenylated proteins; in practice, this is often
achieved using disruptive inhibition of the mevalonate
pathway by statins. Finally, recombinant rat RabGGTase
is most commonly used, and may confer subtle differ-
ences over the human enzyme; rat Rep2 is also not well-
characterized, which throws some doubt on using rat
RabGGTase to study Choroideremia.
As noted above (N-acylation), live-cell metabolic labeling
is particularly powerful for assessment of in-cell potency
and target specificity of transferases, and de novo discovery
of lipidated proteins. Here, the isoprenol analogue is used
since the pyrophosphate has limited cell permeability.
Conversion to the pyrophosphate in situ renders labeling
efficiency dependent on a rescue pathway separate from
the standard isoprenoid biosynthetic pathway, the activity
of which is poorly characterized and varies between cell
types. Statin treatment can be used to deplete the
endogenous pool of isoprenoids and thus upregulate
probe incorporation, but can be strongly disruptive due
to concurrent inhibition of cholesterol biosynthesis. A
recent study elegantly addressed regulation of isoprenoid
uptake through the rescue pathway by means of quanti-
tative mass spectrometry and farnesyl analogues, high-
lighting the importance of considering metabolism when
designing probes and interpreting the data obtained from
studies with chemical reporters [53]. An alkyne-tagged
isoprenoid analogue has been used to study prenylation in
bacterial and viral infection, applying a metabolic labeling
strategy to identify prenylation of Legionella pneumophila
effector proteins by the host prenylation machinery
during intracellular infection [42], and revealing the role
of prenylation of the long isoform of Zinc finger antiviral
protein (ZAP) in the antiviral activity of this protein
[54]. Given the broadening range of reported substrates,
careful characterization of the scope of prenylation in
relevant disease models will be required to realize the
genuine therapeutic potential of PTIs in the clinic.
Metabolic labeling with a 2D gel imaging strategy was
employed to identify targets of a farnesyltransferase
inhibitor (FTI) [55]; whilst a small set of differentially
prenylated proteins were identified at a single FTIwww.sciencedirect.com concentration, the use of 2D gels introduces technical
limitations in reproducibility, sensitivity, target identi-
fication and robust quantification. Unfortunately,  the
analogue used in most studies to date bears an artificial
ether linkage, and studies to date suggest that it fails to
differentiate between prenyl chain lengths and may
result in non-native membrane distribution of sub-
strates, suggesting it is insufficiently biomimetic to
probe the consequences of PTI. However, in future
the full vista of S-prenylation could be opened up
through a combination of improved prenyl analogues
and quantitative gel-free metabolic labeling technol-
ogies previously successfully applied to N-myristoyla-
tion and S-acylation [12,13,25,26].
Glycosylphosphatidylinositol (GPI) anchored
proteins
Glycosylphosphatidylinositol (GPI)-anchored proteins
are an abundant class of glycolipid-bearing cell surface
proteins that provide one of the most important cellular
machineries for extracellular communication in higher
eukaryotes. GPI-anchored proteins are also implicated
in many diseases including cancers, prion diseases and
several parasitic infections [56–58]. Although bioinfor-
matics methods (e.g. PredGPI) can suggest potential
GPI targets [59], experimental approaches for selective
and quantitative profiling of modified proteins at a pro-
teome-wide scale are limited. A recent study provides the
first reported example of PTM-directed enrichment of
GPI-anchored proteins through metabolic chemical tag-
ging of the GPI lipid anchor [12]. Exploiting the prom-
iscuity of cellular fatty acid processing machineries,
incubation of YnMyr with the malaria parasite P. falci-
parum led to metabolic labeling of NMT substrates (see
above) and also GPI-anchored proteins, the latter in-
cluding key mediators of immunogenicity and potential
vaccine targets. A simple base-treatment prior to affinity
enrichment was sufficient to distinguish amide-linked
N-myristoylation from ester-linked GPI O-myristoylation,
and led to the identification of all known and several
novel GPI-anchored proteins. This approach should
prove applicable to global GPI protein profiling in other
(e.g. human) systems.
Protein O-cholesterylation
Protein cholesterylation has so far been observed only in
the hedgehog (Hh) family of secreted proteins, which
undergo posttranslational autocleavage of their C-term-
inal domain with concomitant O-cholesterylation at the
C-terminal acid. Hh proteins are key players in embryonic
development, stem cell maintenance and tissue repair,
and as noted above are aberrantly overexpressed in sev-
eral cancers [15]. Although the effects of loss of choles-
terylation are readily modeled by deletion mutants, many
questions concerning the role of intact wild-type choles-
terylation remain unanswered due to the lack of robust
tools to study the modification in living cells and in liveCurrent Opinion in Chemical Biology 2015, 24:48–57
54 Omicsorganisms. The first report of chemical tagging of cho-
lesterylation focused on the most studied member of the
human Hh family, sonic hedgehog (Shh), and used an
azide-tagged cholesterol analogue in a cell line [60];
whilst labeling was demonstrated, low efficiency and
toxicity limited the scope of questions that could be
addressed. The most recent addition to the protein cho-
lesterylation toolset is a panel of alkyne-cholesterol
analogues displaying far superior performance to previous
probes [17], achieving efficient labeling at low probe
concentration and no cellular toxicity. An optimal probe
provided quantitative profiling of cholesterylation in
multiple pancreatic cancer cell lines with elevated Shh
expression, the first direct evidence for extensive Shh
cholesterylation in secreted multimeric signaling com-
plexes, confocal fluorescent imaging of labeled Shh in
human cells, and visualization of cholesterylated Hh
proteins in zebrafish embryos. It is anticipated that in
future these chemical tools will shed more light on the
roles of cholesterylation in secretion and in the context of
developing organisms.
Perspectives
Rapid progress has been made over the past few years in
our understanding of the global scope and potential
druggability of protein lipidation, due in large part to
the development of quantitative chemical proteomic
technologies that can meet the challenge of analyzing
these large and hydrophobic PTMs. The combination of
tagging with selective inhibitors or other complementary
approaches has proven particularly powerful, and can
further provide unique insights into in-cell inhibitor
target engagement. In the near future, several important
aspects of protein lipidation biology are ripe for further
development.
Enhancing bioinformatic predictions: new chemical proteo-
mics tools for the direct analysis of the sites of protein
lipidation in vivo offer the opportunity to improve bioin-
formatic prediction algorithms, which currently rely on
very limited learning sets [12,13].
Broadening scope: tagging methodologies offer a unique
approach to identifying lipidation at amino acid side
chains beyond N-linkage and S-linkage, and further integ-
ration with advanced mass spectrometry analysis should
enable routine profiling of O-acyl and alkyl side chains.
For example, O-palmitoleoylation (16:1) of Wnt proteins
by the MBOAT family protein Porcupine (Porc) is known
to be critical for Wnt signaling, and has been recognized
as a druggable node in the context of cancer [61].
Prospective PTM discovery: the discovery of the first sub-
strates of myristoylation, palmitoylation, farnesylation and
geranylgeranylation was achieved through radiolabeling;
given the notoriously poor sensitivity of this approach and
historic limitations of proteomics, it is perhaps unsurprisingCurrent Opinion in Chemical Biology 2015, 24:48–57 that these are among the most abundant classes of protein
lipidation in the cell. Robust tag-enrichment technologies
now present the opportunity to systematically profile meta-
bolic incorporation of novel lipids across the proteome, for
de novo discovery of PTMs previously overlooked due to
their rarity or mass spectrometric intractability.
Protein lipidation in disease models: as noted above, the first
proteome-wide studies of lipidation in pathogenic bac-
teria and parasites in a relevant host context have recently
been reported [40,42], and there is much scope for the
application of these tools to study host/pathogen inter-
actions in relevant models of viral infection. Bacterial
lipoproteins, which carry an S-linked diacylglycerol motif,
have previously been probed using tagging approaches in
Escherichia coli [62]; optimized quantitative methods
should be widely applicable in a variety of pathogenic
bacteria, to further illuminate the functional roles of this
key bacterial machinery in virulence.
Interplay with lipid metabolism: lipid metabolism is known
to be dysregulated in many cancers and as a consequence
of therapy (e.g. statin or fatty acid synthase inhibitor
treatment), and there is recent evidence that tissue-
specific lipid metabolism directly impacts the profile of
protein lipidation [63]. The potential for incorporation of
branched lipids, unsaturated fatty acids and cholesterol-
related hormones remains almost unexplored at present,
and the combination of lipidomics with tagging
approaches, as recently explored for prenylation [53],
is likely to reveal a complex interplay between these
systems.
Imaging specific protein lipidation: the widespread nature of
lipids in the cell, both in membranes and on proteins,
renders global analysis by cellular imaging of limited
utility; even in an ideal case, only the overall distribution
of lipids and/or lipidated proteins is revealed [64]. An
exception is cholesterylation which appears to be
uniquely attached to Hh proteins; following clearance
of membrane lipids, this modification can be imaged with
good fidelity [17]. In the first step towards a more
general methodology, Gao and Hannoush, recognizing
that substrate-specific imaging requires protein identity
coupled to covalent modification by a lipid, employed a
combination of palmitoyl tagging and specific antibodies
coupled to oligonucleotides, enabling proximity-directed
detection by rolling-circle amplification [65]. Preliminary
studies suggest that with optimization this rather complex
approach is capable of direct detection of palmitoylation
of Wnt, Hh and Ras proteins [66], but significant
technological hurdles remain if this approach is to be
rendered generally applicable, or of use in live cell
imaging.
The unique PTM-driven, system-wide profiling capabili-
ties of chemical tagging can now be applied in a greatwww.sciencedirect.com
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is currently unknown due to the historical lack of tools
with which to ask key questions: Which substrates are
modified, and where and when does this occur? Which
enzymes and proteins write, erase and read the modifi-
cation, and how are they regulated? To what extent is
lipidation dysregulated in a pathological context, and
where do the therapeutic opportunities lie? It is remark-
able that most of these questions have not yet been
systematically addressed in relevant systems, despite
enormous investment in development of potent and se-
lective inhibitors for several of these pathways, above all
against protein prenylation. It is essential that we under-
stand the global scope and dynamic range of this complex
and widespread class of PTMs before we can unlock the
full therapeutic potential of protein lipidation.
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